Exelixis

Ultime notizie

Titoli nella lingua originale della fonte.

• Exelixis Shares Rising on CABOMETYX Revenue (si apre in una nuova scheda)

  Yahoo Finance · 30 set 2026

• Exelixis stock hits all-time high at 59.73 USD By Investing.com (si apre in una nuova scheda)

  Investing.com UK · 30 set 2026

• Return on equity % of Exelixis, Inc. – HAN:EX9 (si apre in una nuova scheda)

  TradingView · 30 set 2026

• How Investors Are Reacting To Exelixis (EXEL) FDA Review Extension (si apre in una nuova scheda)

  webull.com · 25 set 2026

• Could Zanzalintinib's FDA Delay Affect Exelixis' Growth Plans? (si apre in una nuova scheda)

  Yahoo Finance · 24 set 2026

• Exelixis, Inc. (EXEL) Stock Forecasts (si apre in una nuova scheda)

  Yahoo! Finance Canada · 24 set 2026

• Exelixis (EXEL) Gets FDA Review Extension For Zanzalintinib განაცხად tometastatic Colorectal Cancer (si apre in una nuova scheda)

  Yahoo Finance · 21 set 2026

• Exelixis Eyes Oncology Deals, Readies Zanzalintinib Launch as Cabozantinib Tops $3B (si apre in una nuova scheda)

  Yahoo Finance · 17 set 2026

• Can Exelixis (EXEL) Stay Cheap After A 185% Five Year Run? (si apre in una nuova scheda)

  Simply Wall Street · 17 set 2026

• Exelixis (EXEL) Faces a Three-Month Zanzalintinib Review Extension. Can the Data Support Approval? (si apre in una nuova scheda)

  Yahoo Finance · 16 set 2026

• Exelixis Eyes Zanza Launch as CABOMETYX Growth Faces NET Ramp Hurdle (si apre in una nuova scheda)

  Yahoo Finance · 15 set 2026

• Analysts Offer Insights on NA Companies: Exelixis (EXEL) and Resolution Minerals Ltd. Sponsored ADR (RML) (si apre in una nuova scheda)

  The Globe and Mail · 15 set 2026

• Exelixis: The FDA Delay Costs Less Than The Market Thinks (NASDAQ:EXEL) (si apre in una nuova scheda)

  Seeking Alpha · 14 set 2026

• Exelixis: Why The 3-Month Delay Is More Negative Than It May Seem (Downgrade) (si apre in una nuova scheda)

  Seeking Alpha · 14 set 2026

• FDA delays review of Exelixis' zanzalintinib by 3 months, no new safety issues found (si apre in una nuova scheda)

  Pluang · 14 set 2026

• Exelixis Eyes CABOMETYX Growth, Zanzalintinib Catalysts Across Cancer Franchises (si apre in una nuova scheda)

  Yahoo Finance · 14 set 2026

• Exelixis (EXEL) Gets Longer FDA Review As Cancer Pipeline Milestone Advances (si apre in una nuova scheda)

  Simply Wall Street · 12 set 2026

• FDA extends review of Exelixis drug application for metastatic colorectal cancer (si apre in una nuova scheda)

  Investing.com India · 11 set 2026

• US FDA extends review of Exelixis’ cancer drug (si apre in una nuova scheda)

  WSAU · 11 set 2026

• After FDA nod for novel Cabometyx formulation, analysts predict limited threat to Exelixis (si apre in una nuova scheda)

  Fierce Pharma · 11 set 2026

• Exelixis Says FDA Extended Review Period for Colorectal Cancer Drug (si apre in una nuova scheda)

  Yahoo Finance · 11 set 2026

• Exelixis Shares Fall 3.5% as FDA Extends Zanzalintinib Review by Three Months (si apre in una nuova scheda)

  Yahoo Finance · 11 set 2026

• Exelixis stock falls as FDA extends zanzalintinib review By Investing.com (si apre in una nuova scheda)

  Investing.com UK · 11 set 2026

• Exelixis Stock Slips as FDA Delays Cancer Drug Review, Analyst Weighs In (si apre in una nuova scheda)

  Benzinga · 11 set 2026

• EXEL Stock Slides After FDA Adds Three Months To Cancer Drug Review — William Blair Sees More Swings In Near Term (si apre in una nuova scheda)

  Yahoo Finance · 11 set 2026

• FDA delays approval decision for Exelixis' tyrosine kinase inhibitor in colorectal cancer (si apre in una nuova scheda)

  Fierce Biotech · 11 set 2026

• U.S. FDA extends review of Exelixis' cancer drug (si apre in una nuova scheda)

  Yahoo Finance · 11 set 2026

• US FDA extends review of Exelixis' cancer drug (si apre in una nuova scheda)

  Reuters · 11 set 2026

• Adagene Receives Milestone Payment From Exelixis (si apre in una nuova scheda)

  Yahoo Finance · 9 set 2026

• Exelixis at Wells Fargo conference: zanzalintinib takes center stage (si apre in una nuova scheda)

  Investing.com India · 8 set 2026